Stockscreener 앱 받기
30.86
6.63%
1.92
시간 외 거래:
30.80
-0.06
-0.19%
전일 마감가:
$28.94
열려 있는:
$28.95
하루 거래량:
2.82M
Relative Volume:
1.94
시가총액:
$3.78B
수익:
$588.99M
순이익/손실:
$214.33M
주가수익비율:
18.32
EPS:
1.6844
순현금흐름:
$208.61M
1주 성능:
+4.82%
1개월 성능:
+24.99%
6개월 성능:
+44.34%
1년 성능:
+27.00%
1일 변동 폭
$28.75
$30.96
1주일 범위
$27.66
$30.96
52주 변동 폭
$19.05
$32.56
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
명칭
Catalyst Pharmaceuticals Inc
전화
(305) 529-2522
주소
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
30.86 | 3.54B | 588.99M | 214.33M | 208.61M | 1.6844 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-04 | 개시 | Robert W. Baird | Outperform |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-03-14 | 개시 | Citigroup | Buy |
| 2024-03-07 | 개시 | BofA Securities | Buy |
| 2023-12-21 | 개시 | Oppenheimer | Outperform |
| 2022-08-24 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 재개 | Piper Jaffray | Overweight |
| 2016-10-05 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 재확인 | ROTH Capital | Buy |
| 2014-09-16 | 재확인 | ROTH Capital | Buy |
| 2014-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2013-10-21 | 재확인 | Aegis Capital | Buy |
| 2013-09-24 | 개시 | Maxim Group | Buy |
| 2013-09-06 | 재확인 | Aegis Capital | Buy |
| 2013-04-18 | 개시 | Aegis Capital | Buy |
| 2012-08-27 | 업그레이드 | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | 업그레이드 | Merriman | Sell → Neutral |
| 2009-05-29 | 다운그레이드 | Hapoalim | Neutral → Underperform |
| 2009-05-29 | 다운그레이드 | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 개시 | Merriman Curhan Ford | Buy |
| 2007-11-28 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 개시 | Stifel Nicolaus | Buy |
| 2007-01-05 | 개시 | First Albany | Buy |
모두보기
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
Angelini Interest Puts Catalyst Pharmaceuticals Rare Disease Value In Focus - Yahoo Finance
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Catalyst Pharmaceutics to Report Q1 Earnings: Is a Beat in the Cards? - Yahoo Finance
Italy’s Angelini said to explore Catalyst Pharma acquisition - MSN
Hussman Strategic Advisors Inc. Sells 42,000 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Executive Compensation, Stock Awards, and Option Grants 2025 Overview - Minichart
Catalyst Pharmaceuticals jumps on report of interest from Angelini Pharma - MSN
(CPRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Executive pay, ownership and governance detailed in Catalyst (NASDAQ: CPRX) 2025 10-K/A - Stock Titan
Universal Beteiligungs und Servicegesellschaft mbH Has $3.91 Million Holdings in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
CPRX Stock Price, Quote & Chart | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum - Yahoo Finance
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
From Sun Belt Boom to Biotech Hub: Why Southern Florida’s Moment has Arrived - Pharmaceutical Executive
Catalyst Pharmaceuticals (CPRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026 - 富途牛牛
NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA - TradingView
Catalyst posts Q1 results after the bell May 11; call set for 8:30 ET - Stock Titan
Angelini Pharma Considers Acquisition of Catalyst Pharmaceuticals (CPRX) - GuruFocus
BofA reiterates Catalyst Pharmaceuticals stock rating on M&A report By Investing.com - Investing.com Canada
Catalyst Pharmaceuticals Jumps 6.8% Amid Sector-Wide Rally - AlphaStreet
Catalyst Pharmaceuticals (CPRX) Shares Surge on Acquisition Inte - GuruFocus
Catalyst Pharmaceuticals jumps on report of potential acquisition interest - Quiver Quantitative
Italy’s Angelini Said to Explore Catalyst Pharma Acquisition - Bloomberg.com
Italy's Angelini said to explore acquisition of Catalyst PharmaBloomberg News - marketscreener.com
Catalyst Pharmaceuticals jumps on report of interest from Angelini Pharma (CPRX:NASDAQ) - Seeking Alpha
Catalyst Pharmaceuticals stock surges on takeover report By Investing.com - Investing.com Canada
Organon Shares Rally 16% in Premarket as Sun Pharma Announces Buyout - TradingView
Italy’s Angelini Said to Explore Acquisition of Catalyst Pharma - Bloomberg.com
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y - MSN
Catalyst Pharmaceuticals: Favorable Trial Outcome Could Be A Meaningful Overhang - Seeking Alpha
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Firdapse Momentum And Growing Agamree Contribution - Sahm
Should Stronger Firdapse and Agamree Momentum Require Action From Catalyst Pharmaceuticals (CPRX) Investors? - Sahm
How Rare-Disease Drug Momentum At Catalyst Pharmaceuticals (CPRX) Has Changed Its Investment Story - Yahoo Finance
Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
AbbVie's TrenibotE Receives FDA CRL Due to Manufacturing Issues - TradingView
Catalyst Pharmaceuticals stock hits all-time high at $26.63 By Investing.com - Investing.com Australia
Catalyst Pharmaceuticals (NASDAQ:CPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
Catalyst Pharmaceuticals stock hits all-time high at $26.63 - Investing.com
Is Catalyst (CPRX) stock attracting cautious sentiment | Q4 2025: Better Than ExpectedReal Time Stock Idea Network - Xã Thanh Hà
Catalyst Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
The Bull Case For Catalyst Pharmaceuticals (CPRX) Could Change Following Firdapse Exclusivity Win And Agamree Launch - Sahm
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Recommendation of "Strong Buy" from Brokerages - MarketBeat
KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data - TradingView
Price-Driven Insight from (CPRX) for Rule-Based Strategy - Stock Traders Daily
Catalyst Pharmaceuticals (CPRX) Is Up 5.3% After Stronger Revenue And Expanded M&A PipelineWhat's Changed - Sahm
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case - ChartMill
Catalyst Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch
Institutional Support And Deal Pipeline Shape Outlook For Catalyst Pharmaceuticals - Yahoo Finance
Catalyst Pharmaceuticals Inc (CPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):